The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant

Journal of Hepatology

Volumn 46, Issue 5, 2007, Pages 768-774

  Rendina, Maria ^a   Schena, Antonio ^a   Castellaneta, Nicola Maurizio ^a   Losito, Francesco ^a   Amoruso, Anna Cinzia ^a   Stallone, Giovanni ^a   Schena, Francesco Paolo ^a   Leo, Alfredo Di ^a   Francavilla, Antonio ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Haemodialysis; HCV; Hepatitis; Kidney; Peginterferon; Ribavirin; Transplant

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DERMATITIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEMODIALYSIS; HEPATITIS C; HUMAN; HUMAN TISSUE; IRRITABILITY; KIDNEY TRANSPLANTATION; MALE; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PREOPERATIVE CARE; RENAL DIALYSIS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 34047153283     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.12.016     Document Type: Article

References (45)

1. Pol S., Zylberberg H., Fontaine H., and Brechot C. Treatment of chronic hepatitis C in special groups. J Hepatol 31 Suppl. 1 (1999) 205-209
2. Okuda K., and Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up. World J Gastroenterol 10 (2004) 2209-2212
3. Sezer S., Ozdemir F.N., Akcay A., Arat Z., Boyacioglu S., and Haberal M. Renal transplantation offers a better survival in HCV-infected ESRD patients. Clin Transplant 18 (2004) 619-623
4. Fabrizi F., Poodard F., and Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 36 (2002) 3-10
5. Mathurin P., Mouquet C., Poynard T., Sylla C., Benalia H., Fretz C., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29 (1999) 257-263
6. Bloom R.D., Rao V., Weng F., Grossman R.A., Cohen D., and Mange K.C. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13 (2002) 1374-1380
7. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
8. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
9. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
10. Saab S., and Wang V. Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options. J Clin Gastroenterol 37 (2003) 155-163
11. Encke J., Kraus T., Mehrabi A., Stremmel W., and Sauer P. Treatment of hepatitis C virus reinfection after liver transplantation. Transplantation 80 1 Suppl. (2005) S125-S127
12. Fabrizi F., Dulai G., Dixit V., Bunnapradist S., and Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 18 (2003) 1071-1081
13. Mousa D.H., Abdalla A.H., Al-Shoail G., Al-Sulaiman M.H., Al-Hawas F.A., and Al-Khader A.A. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 36 (2004) 1831-1834
14. Annicchiarico B.E., and Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther 20 (2004) 123-124 author reply 124
15. Rivera M., Gentil M.A., Sayago M., Gonzalez Roncero F., Trigo C., Algarra G., et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 37 (2005) 1424-1425
16. Bruchfeld A., Lindahl K., Reichard O., Carlsson T., and Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hep 13 (2006) 316-321
17. Russo M., Ghalib R., Sigal S., and Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21 (2006) 37-443
18. Kokoglu O., Ucmak H., Hosoglu S., Cetinakaya A., Kantaeceken B., Buyukbese M., et al. Efficacy and tolerability of pegylated-interferon alpha-2a in haemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 21 (2006) 575-580
19. Teta D., Landtwing Luscher B., Gonvers J., Francioli P., Phan O., et al. Pegylated Interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial transplant 20 (2005) 991-993
20. Osella A., Sonzogni L., Cavallini A., Foti L., Guerra V., Di Leo A., et al. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in Southern Italy: a population-based study. J Clin microbial (1999) 2371
21. Schiff E.R., Lai C.L., Hadziyanni S., Neuhaus P., Terrault N., Rendina M., et al. Adefovir dipivoxil therapy for lamivudine resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 38 (2003) 1419-1427
22. Santantonio T., Gynther S., Sterneck m., Rendina M., Messner M., Launois B., et al. Liver graft infection by HBV S-gene mutants in transplant patients receiving long term HBIg prophylaxis. Hepatogastroenterology 46 (1999) 1848-1854
23. Bruchfeld A., Lindahl K., Schvarcz R., and Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 24 (2002) 701-708
24. Bruchfeld A., Stahle L., Andersson J., and Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 8 (2001) 287-292
25. Filimberti E., Cinotti S., Salvadori M., Amato M., Longo G., Nazzari M., et al. Hemodialysis with defibrotide: effects on coagulation parameters. Int J Artif Organs 15 (1992) 590-594
26. Mor E., Pappo O., Bar-Nathan N., Shaharabani E., Shapira Z., Tur-Kaspa R., et al. Defibrotide for the treatment of veno-occlusive disease after liver transplantation. Transplantation 72 (2001) 1237-1240
27. Palmer K.J., and Goa K.L. Defibrotide. Drugs 45 (1993) 259-294
28. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991) 372-374
29. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005) 343-350
30. Ziol M., Handra-Luca A., Kettaneh A., Christidis C., Mal F., Kazemi F., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 (2005) 48-54
31. Camma C., Licata A., Cabibbo G., Latteri F., and Craxi A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother 6 (2005) 399-408
32. Wasley A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20 (2000) 1-16
33. Zeldis J.B., Depner T.A., Kuramoto I.K., Gish R.G., and Holland P.V. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 112 (1990) 958-960
34. Bruchfeld A., Wilczek H., and Elinder C. Hepatitis C infection, time in renal replacement therapy, and outcome after kidney transplantation. Transplant 78 (2004) 745-750
35. Hanafusa T., Ichikawa Y., Kishikawa H., Kyo M., Fukunishi T., Kokado Y., et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplant 27 (1998) 471-476
36. Tokumoto T., Tanabe K., Ishikawa N., Simizu T., Oshima T., Noguchi S., et al. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplant Proc 30 (1998) 3270-3272
37. Cruzado J.M., Casanovas-Taltavull T., Torras J., Baliellas C., Gil-Vernet S., and Grinyo J.M. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 3 (2003) 357-360
38. Kamar N., Toupance O., Buchler M., Sandres-Saune K., Izopet J., Durand D., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14 (2003) 2092-2098
39. Gupta S.K., Pittenger A.L., Swan S.K., Marbury T.C., Tobillo E., Batra V., et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 42 (2002) 1109-1115
40. ®) can be administered safely in patients with end-stage renal disease. Hepatology 34 (2001) A326
41. Martin P., Mitra S., Farrington K., Martin Nancy E., and Modi-Marlene W. Pegylated (40 kDa) interferon alfa-2a (Pegasys™) is unaffected by renal impairment. Hepatology 32 (2000) A370
42. Modi M.W., Fulton Jeffery S., Buckmann D.K., Wright Teresa L., and Moore David J. Clearance of pegylated (40 kDa) interferon alfa-2a (Pegasys™) is primarily hepatic. Hepatology 32 (2000) A371
43. Okuda K., Hayashi H., Yokozeki K., and Irie Y. Destruction of hepatitis C virus particles by haemodialysis. Lancet 347 (1996) 909-910
44. Hayashi H., Okuda K., Yokosuka O., Kobayashi S., Yokozeki K., Ohtake Y., et al. Adsorption of hepatitis C virus particles onto the dialyzer membrane. Artif Organs 21 (1997) 1056-1059
45. Furusyo N., Hayashi J., Ariyama I., Sawayama Y., Etoh Y., Shigematsu M., et al. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol 95 (2000) 490-496